For antibody drug conjugates (ADCs), the fate of the cytotoxic payload in vivo needs to be well understood to mitigate toxicity risks and properly design the first in-patient studies. Therefore, a distribution, metabolism, and excretion (DME) study with a radiolabeled rat cross-reactive ADC ([ 3 H]DM1-LNL897) targeting the P-cadherin receptor was conducted in female tumor-bearing nude rats. Although multiple components [total radioactivity, conjugated ADC, total ADC, emtansine (DM1) payload, and catabolites] needed to be monitored with different technologies (liquid scintillation counting, liquid chromatography/mass spectrometry, enzyme-linked immunosorbent assay, and size exclusion chromatography), the pharmacokinetic data were nearly superimposable with the various techniques. liquid extraction surface analysis coupled to micro-liquid chromatography-tandem mass spectrometry data proved that the lysine (LYS)-4(maleimidylmethyl) cyclohexane-1-carboxylate-DM1 (LYS-MCC-DM1) catabolite was the only detectable component distributed evenly in the tumor and liver tissue. The mass balance was complete with up to 13.8% 6 0.482% of the administered radioactivity remaining in carcass 168 hours postdose. LNL897-derived radioactivity was mainly excreted via feces (84.5% 6 3.12%) and through urine only to a minor extent (4.15% 6 0.462%). In serum, the major part of radioactivity could be attributed to ADC, while small molecule disposition products were the predominant species in excreta. We show that there is a difference in metabolite profiles depending on which derivatization methods for DM1 were applied. Besides previously published results on LYS-MCC-DM1 and MCC-DM1, maysine and a cysteine conjugate of DM1 could be identified in serum and excreta.
Introduction
Antibody-drug conjugates (ADCs) constitute a therapeutic modality in which a cytotoxic agent (payload) is chemically linked via a cleavable or noncleavable linker to a monoclonal antibody (mAb) that recognizes a tumor-associated antigen. To date, three ADCs have been approved for therapeutic use: 1) Gemtuzumab ozogamicin for acute myelogenous leukemia, which has been withdrawn from the market; 2) Brentuximab vedotin for Hodgkin's lymphoma; and 3) the most recently approved trastuzumab ado-emtansine for second-line treatment of HER2-positive metastatic breast cancer). While the goal of using ADCs as therapeutics is to minimize or localize toxicity with the antibody intended to target specific tissue(s), toxic changes with these agents can been seen in multiple tissues (van der Heiden et al., 2006; de Claro et al., 2012; Poon et al., 2013; Yan et al., 2016) . Toxicities observed with ADCs may be associated with either the components of the ADC (antibody, linker, and payload), or the metabolites. Therefore, the fate of the ADCs in vivo needs to be well understood to mitigate toxicity risks and properly design the first in-patient studies. Up to now, little has been published about the distribution and uptake of ADCs . Therefore, tissue distribution as well as metabolism and excretion data can be very useful to support pharmacokinetics and pharmacodynamics as well as safety assessment in that they provide insights of drug levels at the site of action, e.g., in tumors (Wada et al., 2014) . In addition, they may be used for mechanistic investigations, e.g., to explore sites of unexpected drug clearance or for characterization of target-mediated drug disposition. Therefore, these data can be considered as a powerful tool in relation to learning about disposition, pharmacokinetics and pharmacodynamics, and toxicity of ADCs.
The bioanalytical and distribution, metabolism, and excretion (DME) properties of antibody maytansinoid-based ADCs have been recently reviewed (Erickson and Lambert, 2012; Kaur et al., 2013; Deslandes, 2014; Han and Zhao, 2014; Thudium et al., 2013; Marcoux et al., 2015; Beck et al., 2016; Kraynov et al., 2016) The fate of antibody maytansinoid conjugates was investigated in naive or tumor-bearing mice and naive rats with iodine labels on the antibody or a tritium label on emtansine (DM1) (Xie and Blättler, 2006; Shen et al., 2012a; Saad et al., 2015) . The measured tissue exposures were low compared with blood and the main components in serum were attributed to ADC. The main catabolites in serum and excreta differed depending on whether the ADC used a cleavable linker or a noncleavable linker. With a cleavable linker, the main catabolite in mouse liver was DM1 (Sun et al., 2011) , while with the noncleavable 4(maleimidylmethyl) cyclohexane-1-carboxylate (MCC) linker the main catabolites detected in rat were MCC-DM1 and lysine (LYS)-MCC-DM1 (Sun et al., 2011; Saad et al., 2015) . Since released DM1 has been reported to bind to proteins (Davis et al., 2012) , derivatization methods using N-ethyl-maleimide (NEM) and tris(2-carboxyethyl) phosphine (TCEP) are usually applied (Shen et al., 2012a) .
This paper describes a DME study for an ADC with a tritiumlabeled DM1 and MCC linker conducted in female tumor-bearing nude rats against P-cadherin, which is overexpressed in mammary carcinomas (Albergaria et al., 2011) . A P-cadherin-targeted ADC approach is currently explored in the clinic as a novel promising therapy for patients suffering from breast cancer (Menezes et al., 2015) . The key questions we wanted to address in this study were if the tritium-labeled ADC with higher specific activity would be sufficiently stable to perform quantitative whole-body autoradiography (QWBA) to study the tissue distribution in depth. We were particular interested in investigating the extent of distribution between tumors and other tissues, since this can differ, and seeing if QWBA can give additional insights compared with previously published tissue harvesting methods (Shen et al., 2012a) . To investigate if the radioactivity (RA) in tumors can be attributed mainly to intact ADC or small molecule catabolites, tumors were analyzed at different time points to establish kinetics. In addition, complimentary investigations using the newly developed liquid extraction surface analysis microliquid chromatography-tandem mass spectrometry (LESA-mLC-MS/ MS) technique (Lanshoeft et al., 2016) were performed on tumor tissue for the first time. For the bioanalytical methods applied, we wanted to investigate if size exclusion chromatography (SEC) coupled to RA detection provides similar results for pharmacokinetic assessments of ADC as can be obtained by the enzyme-linked immunosorbent assay (ELISA), and/or if SEC-RA can provide additional benefits. Finally, since the catabolism of antibody maytansinoid conjugates has been previously described (Shen et al., 2012a; Widdison et al., 2015) , these current data compare the metabolic profiles with and without applying derivatization methods to gain new insights into catabolism.
Material and Methods

Test Compound and Reference Standards
For the purpose of this study, an ADC with a MCC linker was labeled with tritium in the chemically stable aromatic methoxygroup of the DM1 moiety. The reference standards LYS-MCC-DM1, MCC-DM1, as well as DM1 (structures described in Sun et al., 2011 and Fig. 8) were kindly provided by ImmunoGen, Inc. (Waltham, MA) .
In Vivo Experiments for Radiolabeled ADC
All procedures on animals were conducted in Basel, Switzerland, in accordance with the Swiss Animal Welfare Legislation and authorized by the cantonal veterinary office of Basel-Stadt (license number: BS-1975 and BS-2639;  http://www.veterinaeramt.bs.ch/tierschutz/tierversuche.html). Nude rats were provided by TaconicArtemis (Cologne, Germany). Tumor transplantation was performed in accordance with animal license. For the tumor transplantation, the human breast carcinoma cell line HCC70 was cultured under standard conditions. The cells were harvested, resuspended, and injected subcutaneously into the hind left flank of the female nude rats. The tumors were allowed to grow until they reached a mean volume of about ;250-400 mm 3 before dosing with [ 3 H]DM1-LNL897 was initiated. For dosing, [ 3 H]DM1-LNL897 was dissolved in water containing 10 mM citric acid and 135 mM sodium chloride (pH 5.5). The rats received an intravenous bolus injection in the vena saphena of nominal 10 mg radiolabeled ADC/kg under light inhalation anesthesia using an oxygen/ isoflurane mixture (97/3, v/v; isoflurane: Forene, Abbott AG, Zug, Switzerland). The total amount of RA administered was nominal 50 MBq/kg (where MBq denotes megabecquerel).
After dosing, blood was collected from the sublingual vein of three tumorbearing nude rats at 1, 24, 96, and 168 hours postdose. From each time point the blood was processed to serum by allowing it to clot for at least 30 minutes at room temperature, followed by centrifugation at 2500g for 15 minutes at 4°C. A small aliquot was taken for total RA detection and the remainder of the material was snap frozen and stored at 280°C until further analysis. From a second group of tumor-bearing nude rats, tumors were collected at the same time points as for the rats where blood had been collected (N = 1 rat/time point). In addition, selected animals (N = 3 tumor-bearing nude rats) were housed in metabolic cages for urine and feces collection, allowing determination of the route of excretion and the mass balance. QWBA was performed in a last group of animals at 1, 24, 72, 96, 168, and 264 hours postdose using one animal per time point.
Analytical Methods
Radiometric Analysis. Radioactive signals in the different matrices were quantified by liquid scintillation counting (LSC), using Liquid Scintillation Systems 3500 TR from the Packard Instrument Co. (Meriden, CT). For quench correction, an external standard ratio method was used. Quench correction curves were established by means of sealed standards (Packard Instrument Co.). Background values were prepared for each batch of samples according to the respective matrix. The limit of detection was defined as 1.8 times the background value. All determinations of RA were conducted in weighed samples. To determine possible formation of tritiated water, samples were analyzed twice: direct measurements of RA and after drying of the sample (at 37°C for at least 12 hours). Dried or nondried serum and urine were mixed with scintillation cocktail directly, whereas whole blood and feces samples were solubilized before RA analysis. Measured RA for blood, plasma, and tissues was converted into concentrations (mol Eq per volume or gram) considering the specific RA and assuming a matrix density of 1 g/ml.
Quantitative Whole-Body Autoradiography. Rats were sacrificed by deep isoflurane inhalation. After deep anesthesia, blood for RA determination by LSC was collected from the sublingual vein. The animals were then submerged in n-hexane/dry ice at 270°C for approximately 30 minutes. The embedded carcasses were stored at 218°C and all subsequent procedures were performed at temperatures below 220°C to minimize diffusion of radiolabeled materials into thawed tissues. Sections were prepared as follows: in brief, 40-mm-thick lengthwise dehydrated whole-body sections were prepared and exposed to Fuji BAS III imaging plates (Fuji Photo Film Co., Ltd., Tokyo) in a lead-shielded box at room temperature for 2 weeks. Afterward, the sections were scanned in a Fuji BAS 5000 phosphor imager (Fuji Photo Film Co., Ltd.) at a 50-mm scanning step. The concentrations of total radiolabeled components in the tissues were determined by comparative densitometry and digital analysis of the autoradiogram as described in Schweitzer et al. (1987) ; blood samples of known concentrations of total radiolabeled components processed under the same conditions were used as calibrators.
LESA-mLC-MS/MS. For mass spectrometric detection, whole-body sections were lyophilized at 240°C overnight and mounted on metal glass-slides plates, after which they were placed on a Perfection V370 flatbed scanner (Epson, Kloten, Switzerland) to acquire an optical image. A PAL Autosampler from CTC Analytics AG (Zwingen, Switzerland) was used for extraction of the analytes from the tissue surface at predefined sampling spots using a standard 100 ml PAL syringe from Hamilton Company (Reno, NV). Droplets on the sections were deposited and extracted using a modified CTC Autosampler (CTC Analytics AG, Schlieren, Switzerland). The extracted analytes were injected into an Ekspert microLC 200 system from Eksigent (Dublin, CA) coupled to an API4000 triple quadrupole mass analyzer system (AB SCIEX, Toronto, Canada). The extraction with 2 ml of extraction solvent resulted in a spatial resolution of 2 mm, observing specific transitions for MCC-DM1 and LYS-MCC-DM1 in the mass-to-charge ratio (m/z) range from 100 to 1300. A detailed overview of the principle experimental setup has been described recently (Lanshoeft et al., 2016) .
Quantification of Whole and Conjugated ADC by ELISA. In the serum samples, total antibody concentrations (reflecting conjugated and unconjugated forms of the ADC) were quantified using an ELISA. With this ELISA, all ADC species available in the systemic circulation independent of the status of DM1 conjugation [drug-to-antibody ratio (DAR) 0-8] were measured. In addition, conjugated antibody concentrations (ADC) of all ADCs bearing at least one conjugated DM1 were also measured using an ELISA. The ELISA for the measurement of conjugated ADC used an anti-maytansine antibody as the capturing reagent (provided by ImmunoGen, Inc.), which was immobilized on microtiter plates. Digoxigenin-labeled anti-human-specific antibody followed by anti-digoxigenin/fragment antigen-binding/peroxidase was used for detection by colorimetric readout. The same concept was used for the total antibody assay. However, in this case anti-human-specific antibodies were used for capturing and detection.
For measurement of the ADC, biotinylated anti-maytansinoid mAb immobilized on a streptavidin-coated microtiter plate was used as the capturing antibody. A second antibody, digoxygenin-labeled anti-human fragment crystallizable (Fc) mAb (R10) was used, which binds to the Fc part of the ADC and was detected by anti-digoxigen in the fragment antigenbinding region labeled with peroxidase and 3,39-5,59-tetramethylbenzidine as the substrate. The optical density was measured at 450 nm. The same concept was used for the total antibody assay. However, in this case monoclonal R10 antibody (anti-human Fc-specific mAb) was used to capture the ADC and a polyclonal goat anti-human Fc antibody was used for detection. The lower limit of quantification for both assays (ADC and total antibody) was 0.0991 mg/ml DM1-LNL897 in a 100% matrix; the upper limit of quantification for both assays (ADC and total antibody) was 2.13 mg/ml DM1-LNL897 in a 100% matrix.
Determination of Payload DAR and Drug-Load Distribution in Dosing Solution. The DAR as well as the distribution of the different ADC species (where D represents the number of DM1 molecules covalently attached to the antibody: D0, D1, D2, D3, D4, D5, D6, D7, and D8) in the dosing solution was determined using high-performance liquid chromatography (LC) with mass spectrometry (MS) detection.
To calculate the ADC distribution by MS, the dosing solution (20 ml) was diluted into 80 ml of mobile phase A (0.1% formic acid in water). The diluted dosing solution was injected (50 ml) and separated on a MassPrep on-line desalting cartridge 10 Â 2.1 mm (Waters, Milford, MA) with a flow rate of 0.4 ml/min. The mobile phase was composed of 0.1% formic acid in water (Eluent A) (Fisher Scientific AG, Reinach, Switzerland) and acetonitrile containing 0.1% formic acid (Eluent B) (Sigma Aldrich GmbH, Buchs, Switzerland). The gradient condition was maintained at 10% B for 1 minute, ramped to 80% B for 5 minutes, kept at 80% B for the next 4 minutes, and then returned back to 10% B for 1 minute. After the chromatography, the effluent was split into a ratio of 1:3 with the smaller portion directed into the MS interface and the bigger portion used for radiodetection. Mass measurements were made online using a Synapt G2-Si HDMS mass spectrometer from Waters operating under MassLynx (version 4.1; Waters, Milford, MA) for instrument control, data acquisition, and data processing. From 0 to 12 minutes, the mass spectrometer was operating in positive electrospray ionization mode and scanning from m/z 400 to 4000 with a resolution of 9000.
The total ion chromatogram was selected and the corresponding time-of-flight MS mass spectrum was extracted at a representative time window (containing signals from ADCs of interest) to determine the drug load distribution. The characteristic mass spectrum was deconvoluted using the MaxEnt1 algorithm in MassLynx. The resulting processed mass spectrum (see Fig. 1 ) showed different groups of peaks corresponding to the different numbers of conjugated payloads. Various glycan forms were also observed for each group of a specific payload, since no deglycosylation procedure was applied. The area under each peak was measured using the Radiostar software, version 5.12.0.3 (Berthold Technologies, Bad Wildbad, Germany) and the sum of the peak areas for each group was determined. The relative percentage ratio of individual ADC species to total peak area corresponds to the relative abundance of each ADC species (distribution):
where RAA i denotes the percentage of relative abundance of each ADC species (see the aforementioned distribution calculation; for the assessment it was assumed that all ADC species have the same ionization efficiency). Determination of ADC in Serum and Excreta by SEC and Radiometry. A high-performance LC system (model 1100; Agilent Technologies, Santa Clara, CA) equipped with a binary capillary pump, a column oven, an autosampler, and a diode array detector was used. Then, 15 ml of each serum sample was injected on a Yarra SEC 3000; 300 Â 7.8 mm, 3 mm SEC column (Yarra SEC 3000; 300 Â 7.8 mm, 3 mm, from Phenomenex Inc., Torrance, CA) equipped with a GFC 3000m 4 Â 3 mm i.d. guard column (GFC 3000m 4 Â 3 mm i.d. from Phenomenex Inc.). The column was maintained at 60°C. The ADC was eluted isocratically with 200 mM ammonium acetate (pH 7) containing 15% isopropanol and an isocratic at a flow rate of 0.40 ml/min, which was maintained for 60 minutes. The column effluent was collected in 6-second fractions on yttrium silicate scintillator-coated 96-well plates (LumaPlates; Packard BioScience, The dosing solution was analyzed by LC-MS using a desalting cartridge. Representative deconvoluted mass spectra at day 1 (day of dosing) and day 5 of the dosing solution being stored at 4°C were compared and are shown here. The different groups of peaks were annotated by Dn, where n corresponds to the number of conjugated DM1 molecules per antibody. Each group is composed of four main peaks and several minor components that correspond to the different glycosylation forms. Since no deglycosylation procedure was used for this analysis, the [ Groningen, The Netherlands) from 0 to 40 minutes using a fraction collector GX271 (Gilson, Villiers-le-Bel, France). The plates were dried and counted for 5 minutes in triplicate on a Packard TopCount instrument (PerkinElmer, Waltham, MA). To determine the presence of intact monomeric ADC [ 3 H]-DM1-LNL897 in excreta, aliquots of urine and feces pools (group 2, T 0-168h ) were centrifuged at 20,000g for 15 minutes at 12°C, and 15 ml of the respective supernatants were directly injected onto the SEC column as previously described.
Determination of DM1 and Catabolites in Serum, Urine, and Feces. Urine and feces samples from three animals collected between 0 and 168 hours were pooled by combining equal percentages (by weight) of individual fractions. For serum, equal volumes taken from three rats at the same time postdose were mixed. Since DM1 has a thiol function, it can dimerize in solution under mild oxidative conditions and/or form disulfide bonds with thiol-containing molecules such as cysteine in serum (Shen et al., 2012a) . Therefore, before extraction, serum pools as well as urine pools and feces-homogenized pools were split into two equal parts, after which one was incubated with an equal amount (v/v) of 0.5 M TCEP (Sigma Aldrich GmbH, Steinheim, Germany) for 2 hours at room temperature in the dark. The TCEP is used as a reducing agent to reduce any disulfides (including S-bound DM1) in the sample. The resulting free thiol groups were then alkylated by addition of a 4-fold amount (v/v) of 0.2 M NEM (Sigma Aldrich GmbH) to the incubation solutions in order to prevent further reaction. The samples were stored for two additional hours after addition of NEM (at room temperature in the dark) before further extraction.
The treated and untreated serum and feces samples were then extracted by protein precipitation as follows. Aliquots of sample pools with and without TCEP treatment were stirred for 1 hour with four volumes of acetonitrile followed by centrifugation at 10,000g for 30 minutes. After decanting the supernatants, the RA in the pellets was determined and the recoveries of extraction were calculated. The supernatants were evaporated to dryness under a stream of nitrogen at room temperature and the obtained residues were reconstituted in two volumes (equivalent to original feces/serum volume) of water/acetonitrile (95/5 v/v).
All extracts as well as TCEP treated/untreated urine samples were directly injected (injection volume 20-50 ml) into an ultra-performance liquid chromatography (UPLC) system (Waters) with off-line RA and MS detection. The UPLC system was equipped with two pumps, a column oven, a diode array detector, and an autosampler (CTC PAL 2777) from CTC Analytics AG. The chromatographic system was in line with a fraction collector GX271 (Gilson) and a quadrupole timeof-flight tandem mass spectrometer, Synapt HDMS (Waters) operating under Masslynx, version 4.1, for instrument control, data acquisition, and data processing. Samples were injected on a reverse-phase C18 column Acquity HSS T3; 150 Â 2.1 mm; 1.8 mm particles (Waters, Baden-Dättwil, Switzerland) equipped with an Acquity guard column (5 Â 2.1 mm; 1.5 mm particles; Waters). The column was maintained at 40°C, and the flow rate on the column was 0.45 ml/min. Eluent A was made up of 20 mM ammonium formate including 0.1% of trifluoroacetic acid (pH 3.5), and Eluent B was made up of acetonitrile. The gradient was maintained at 5% B for 2 minutes, ramped to 35% B for 3 minutes, increased slowly to 55% B for 15 minutes and then to 90% B for 5 minutes, kept at 90% B for 5 minutes, returned back to 5% B in 5 minutes, and finally equilibrated for 5 minutes before next injection (for a total run time of 40 minutes). After elution from the column, the effluent was split into a ratio of 1:6 with the smaller portion directed to the MS source, while the remaining flow was collected in 3-second fractions on 96 LumaPlates (Packard BioScience) from 0 to 30 minutes. The plates were dried and counted (up to 30 minutes per well, depending on the level of RA) on a Packard TopCount instrument (PerkinElmer). From the relative peak areas, the concentrations of individual radiolabeled components in serum and the amounts of individual radiolabeled components in the excreta were calculated as follows:
and
where C i,serum denotes the concentration of radiolabeled component i in the serum (on a molar basis); C RA,serum denotes the concentration of total radiolabeled components (RA) in the serum (on a molar basis); R SP denotes the recovery of RA after sample preparation (%); RPA i denotes the relative peak area of radiolabeled component i in the radiochromatogram (percentage of the total area under the radiochromatogram); A i,excreta denotes the amount of radiolabeled component i in the excreta (urine, feces; percentage of the dose); and A RA , excreta denotes the amount of total radiolabeled components (RA) in the excreta (urine, feces; percentage of the dose).
Determination of ADC and Its Catabolites in Tumor Tissues. For metabolic profiling, collected tumor tissues were homogenized separately using a Covaris CryoPrep (Woburn, MA). After extraction, samples were analyzed by LC-MS. Each tumor was weighed and placed in the center of the flexible pouch of a TT05 Tissue Tube (Covaris) using tweezers. The sample was frozen by immersing the flexible pouch into liquid nitrogen, and the tissue was pulverized using a Covaris CryoPrep. The tissue particles were then transferred into a 2-ml preweighed Protein LoBind tube from Eppendorf (Hamburg, Germany), weighed, and homogenized with 10 parts of water (w/w) using a PT1200 Polytron (Kinematica, Eschbach, Germany). Afterward, an aliquot of each tumor homogenate was treated with TCEP (according to the derivatization method described previously) and a second one was processed without treatment. Both samples were extracted as follows: a 4-fold amount (v/w) of acetonitrile was added to the treated and untreated tumor homogenates and the mixture was stirred (750 rpm) for up to 3 hours, followed by centrifugation at 20,000g for 30 minutes at 12°C. The remaining supernatant was evaporated to dryness under a stream of nitrogen at room temperature. The residues of untreated tissues were then reconstituted in one volume (equivalent to the original tumor homogenate volume) of water/acetonitrile (95/5, v/v), while residues of derivatized tissue samples were reconstituted in two volumes of water/acetonitrile (95/5, v/v). Tumor extracts (80 ml) were injected onto an UPLC system with off-line RA and MS detection for determination of free drugs and catabolites (see the instrumentation and conditions for analysis of free DM1 and catabolites in serum, urine, and feces). To determine the presence of intact monomeric ADC [ 3 H]DM1-LNL897 in tumors, homogenized tissues were centrifuged at 18,000g for 20 minutes at 12°C and the recovered supernatants were directly injected (25 ml) on the SEC system described previously.
The RA amount in tumor homogenates was measured by LSC as described previously. All determinations of RA were conducted in weighed samples. The   TABLE 2 Pharmacokinetic parameters of total radiolabeled components in selected tissues of female tumor-bearing nude rats following a single nominal 10 mg/kg i.v. dose of
The T/B ratio is the tissue to blood ratio of C max and AUC last , normalized to the respective blood value estimated by QWBA. ); W tumor denotes the tumor weight (g); and 60 denotes the conversion factor (Bq to dpm).
Peaks in the radiochromatograms were integrated manually using the Radiostar software (Berthold Technologies). From the relative peak areas, the concentrations of individual radiolabeled components in tumor were estimated as follows: Pharmacokinetic Analysis. Pharmacokinetic parameters in serum and tissues were calculated using Phoenix WinNonlin software (Pharsight Corp., Mountain View, CA). The pharmacokinetic estimations were based on a noncompartmental analysis model. The tissue-to-blood C max and the area under the curve (AUC) from the 0 hour to the last measured time point (AUC last ) ratios were calculated when possible. The AUC last was calculated using the linear trapezoidal rule. The half-life was calculated for those tissues and matrices where at least three measurable data points were available in the terminal phase of the tissue concentration time course.
Results
Purity, Composition, and Stability of Dosing Solutions
The radiopurity of [ 3 H]DM1-LNL897 ADC in the dosing solution was determined by SEC to be 94.5% pure (ADC monomer) with 2.94% accounted for by soluble aggregates and 2.56% by small molecule components (data not shown). In addition to radiochemical purity measurements of [ 3 H]DM1-LNL897 ADC in the dosing solution, the relative distribution of different ADC species (0-8 DM1 molecules attached to antibody) as well as the DAR were determined by MS (Fig. 1) . The deconvoluted mass spectrum revealed relative area ratios of 3.3%, 11.7%, 19.7%, 22.7%, 18.2%, 12.5%, 6.3%, 3.9%, and 1.8% for ADCs D0, D1, D2, D3, D4, D5, D6, D7, and D8, respectively (where Dn corresponds to the number of covalently bound payload DM1). After five days at 4°C, the sample was remeasured and a comparable distribution was observed (1.2%, 10.4%, 20.5%, 25.2%, 19.9%, 13.6%, 5.8%, 2.6%, The concentrations of total radiolabeled components, as well as the total and conjugated antibodies in serum were measurable throughout the observation period up to 168 hours postdose ( Fig. 2; Table 1 ). The ADC was eliminated with mean half-lives ranging from 51.3 hours (based on RA measurements by LSC) to 62.2 hours (based on conjugated antibody measured by ELISA). The AUC last of total and conjugated antibodies amounted to 62.3 and 73.4 hours/mM, respectively (Table 1) , which represented ;99.8% and 117% of the AUC last value of total radiolabeled components, respectively. The concentration data acquired by SEC-RA measurements were in good agreement with the ELISA-derived data ( Fig. 2 
H]DM1-LNL897 to Female Tumor-Bearing Nude Rats
The tissue distribution data are summarized in Table 2 . Representative QWBA images are shown in Fig. 3 . Total radiolabeled components were extravascularly distributed throughout the body to a minor extent. In selected tissues given in Table 2 and shown in Fig. 3 , total radiolabeled components were quantifiable up to 264 hours postdose. In 20 out of 36 tissues, T max was rapidly reached at 1 hour postdose, the first time point analyzed. In 10 out of 35 tissues, T max was reached at 24 hours postdose, the second time point analyzed. In the remaining tissues, T max was reached at 72 hours postdose. Only hair (tactile) showed a T max value 168 hours postdose. The highest C max values were determined for lung (0.679 nmol/g), tumor (0.575 nmol/g), liver (0.595 nmol/g), adrenal gland (medulla) (0.573 nmol/g), ovarian tissue (0.556 nmol/g), spleen (red pulp) (0.506 nmol/g), and kidney (medulla)(0.494 nmol/g). In all tissues analyzed, exposure based on C max was lower in comparison with blood (QWBA) (1.15 nmol/g).
The highest AUC last values were determined for tumor (85.6 h·nmol/g), adrenal gland (medulla) (52.7 h·nmol/g), spleen (red pulp) (49.2 At 264 hours postdose, total radiolabeled components were still detected in the analyzed tissues, which is in line with the high fraction of RA determined in the carcass at the end of the excretion experiment (13.8% 6 0.482% of the dose) (Table 8 ). In many tissues a half-life (T 1/2 ) was calculated. The tissues showed varying half-lives ranging from 62.4 hours for stomach (glandular) to 94.2 hours for eye (choroid).
Metabolic Stability of [
3 H]-Label for DM1 and ADC. Since we have synthesized radiolabeled ADC with high specific activity, the formation of tritiated water was retested and calculated according to Tse and Jaffe (1991) . Total radiolabeled components measured in urine condensates of individual rats after lyophilization indicated that a very low fraction of the administered RA was transformed into tritiated water (0.826%-1.01% of the dose), indicating that the [ 3 H] label showed acceptable metabolic stability (data not shown).
Characterization of [ 3 H]DM1-LNL897 and Catabolites
In Fig. 1 , the deconvoluted mass spectrum of [ (Beck et al., 2013) . By applying a collision energy of 45 eV in the trapping cell (MS/MS experiments with collisional energy switching), two characteristic fragment ions at m/z 547 and 485 were observed, corresponding to intact maysine and maysine after loss of water and carbon dioxide, respectively, as described in Liu et al. (2005) . The presence of these two signature ions confirmed that the detected proteins correspond to the [ 3 H]DM1-LNL897 since they are characteristic for the fragmentation of the payload DM1.
In general, the metabolite identification was challenging due to the low abundance of catabolites. The structural characterization of metabolites in different matrices (serum, urine, feces, and tumor) was carried out by LC-MS/MS and peaks were assigned as shown in Figs. 4-7 . However, the poor ionization by electrospray of this class of DM1-containing species, combined with their very low concentration in biologic samples, created significant technical challenges for their identification using LC-MS/MS. As a result, no mass spectral data could be acquired for components P1 and P1.8 (front peaks, Fig. 4) , and as well as for peaks summarized as unidentified residual RA in Fig. 6 . Nevertheless, structural proposals and identification of metabolites such as MCC-DM1 and LYS-MCC-DM1, which have been characterized 
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before for ADCs using the same payload/linker combination (Erickson et al., 2010; Sun et al., 2011; Shen et al., 2012a) , were supported by comparison with synthetic reference standards whenever possible. Other metabolites such as M6 (maysine), which has been previously published as a disposition product of maytansine (Suchocki and Sneden, 1987) and M7 (cysteine conjugate), were characterized in serum samples following protein precipitation by LC-MS/MS (Fig. 4) . In excreta samples ( Fig. 6, urine; Fig. 7 , feces) metabolites M1 (MCC-DM1) and M2 (LYS-MCC-DM1) were identified. Mass spectral data of all characterized components are summarized in Table 3 . Additional information about the chemical structures of metabolites was acquired by reduction of the disulfide bonds using TCEP and by alkylation of the resulting free thiol groups with NEM. This derivatization process was previously tested using a spiked rat serum with a DM1 dimer (positive control) by LC-MS. The presence or absence of NEM-conjugated DM1 in derivatized biologic samples indicated that DM1 was conjugated to endogenous thiol-containing molecules via disulfide bonds. The structures of all identified disposition products of LNL897 are shown in Fig. 8 .
Metabolite Profiles in Serum. Size exclusion off-line radioprofiles of [ (Table 4) , which is slightly lower than the 73.4 mM·h measured by the ELISA method (Table 1 ). The total radiolabeled components corresponding to free small molecule components together accounted for only 1.99% of (Table 5 ). These results suggested that free small molecule components in serum represent only a minor proportion compared with the intact ADC or other protein-bound DM1-containing components in precipitated pellets. The metabolite profiles of the serum supernatant fractions (Fig. 4) showed two early eluting components: P1 and P1.8. For both of these, no mass spectral data could be acquired. Since the front peaks were still present after drying and solvent evaporation, prior to off-line RA measurement, the presence of tritiated water in the front peaks could be excluded. The [ 3 H]-AUC 0-168h for P1 and P1.8 accounted for 0.395% and 0.0640% of total radiolabeled components (Table 5) . MCC-DM1 (M1), LYS-MCC-DM1 (M2), maysine (M6), and a DM1-cysteine conjugate (M7) were identified by MS and accounted for 0.0575%, 0.0611%, 0.0664%, and 0.0907% of [ (Table 5) .
After derivatization, a new peak corresponding to derivatized DM1 (M5, DM1-NEM) appeared (Fig. 4) and accounted for 0.635% of AUC 0-168h (Table 5 ). The radiochromatographic background was higher after derivatization between 5 and 15 minutes postinjection, which potentially indicates that the antibody degraded during the procedure, forming artifacts. The recoveries of RA after extraction of untreated serum samples were found to be 0.9%, 0.8%, 0.8%, and 0.7%, for time points 1, 24, 96, and 168 hours, respectively. For the TCEP-derivatized samples, the recoveries were 4.1%, 3.9%, 4.8%, and 5.2% at the equivalent time points.
Metabolite Profiles in Tumor. In tumor, the concentration of total radiolabeled components was between 110 and 137 pmol·g 21 for the four rats. The derived concentrations for [ 3 H]DM1-LNL897 and LYS-MCC-DM1 are listed in Table 6 . Analysis of rat tumors collected after 1, 24, 72, and 168 hours also demonstrated that the intact [ 3 H]DM1-LNL897 was the major component at 1 hour postdose, increased slightly at 24 hours postdose, and then decreased with time. The fraction representing the small molecules increased from 1 to 72 hours postdose. After 168 hours postdose, the fraction representing the intact ADC was small compared with the fraction representing the small molecule catabolites (Fig. 5) . The metabolite profiles following protein precipitation (Fig. 5) showed LYS-MCC-DM1 (M2) to be the major catabolite, which had a concentration in the tissue between 159 and 307 pmol·g 21 (Table 6 ). An additional minor radiolabeled component, eluting between 7 and 8 minutes, was detected but could not be identified by MS due to the low concentration and the poor ionization by electrospray. Radiochromatograms of tumor homogenates treated with TCEP (reducing agent) resulted in a new small peak eluting at 15 minutes, which corresponds to the retention time of DM1 derivatized with NEM (data not shown). 1  1  93  2550  3410  1550  1  2  0  2490  2800  1610  1  3  29  1740  2750  2430  2  4  0  2540  3010  1780  2  5  0  3620  1400  2220  2  6  0  3030  2280  1310  Mean  20  2662  2608 
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Concentrations of Catabolites in Tumor and Liver Tissues Determined by LESA-mLC-MS/MS. Complimentary tumor data analyzed by LESA-mLC-MS/MS from tumors of different animals were acquired and compared with RA measurements (Fig. 9) . Three different sampling locations on two separate slices could be probed and the results suggested a homogenous distribution of LYS-MCC-DM1 catabolite (Table 7) . Although these tumors were collected from different animals, and measured by a different technique, the measured concentration data are in alignment with the radioprofiling data (Fig. 9) . The sensitivity of LESA-mLC-MS/MS allowed specific detection of the main catabolite LYS-MCC-DM1 (M2) in tumor sections.
Metabolite Profiles in Urine. Analysis of rat urine (0-168 hours) by SEC (data not shown) showed no peak corresponding to the retention time of the intact [ 3 H]DM1-LNL897 (based on the retention time of the standard). The remaining part of excreted RA represented small molecule components, which were analyzed by UPLC/MS with off-line RA detection in the presence and absence of reducing agent TCEP. The results showed that only a small fraction of the dosed RA, equivalent to 4.15% between 0 and 168 hours (Table 8) , was recovered in urine. The metabolite profile in the urine pool showed M2 (LYS-MCC-DM1) as the major identified radiolabeled component (1.69% of the dose) and M7 (DM1-cysteine conjugate) representing 0.621% of the dose (Table 8) .
Other minor radiolabeled components such as M1 (MCC-DM1) and M6 (maysine) accounted for 0.0946% and 0.0265% of the dose, respectively. In addition to the aforementioned components, the radioprofile showed unresolved baseline RA and a front peak (P1), which combined accounted for 1.41% of the dose ( Fig. 6 ; Table 8 ). Treatment of the urine pool with TCEP resulted in a new small peak in the radiochromatograms (0.127% of the dose). This eluted after M1 and corresponded to DM1 derivatized with NEM (M5).
Metabolite Profiles in Feces. In feces, 84.5% of the dose was excreted between 0 and 168 hours (Table 8 ). The most abundant metabolites in feces were M1 (MCC-DM1), which accounted for 42.5% of the dose, and M2 (LYS-MCC-DM1), which represented 12.7% of the dose (see Fig. 7 ; Table 8 ). Metabolite M7 (DM1-cysteine conjugate) was identified based on retention time and accounted for 1.96% of the dose.
Additional unknown radiolabeled components, such as front peak P1 (0.320% of the dose) and P24 representing 1.79% of the dose, were detected in rat feces between 0 and 168 hours. The sum of residual unresolved RA accounted for 16.8% of the dose. 3 H]DM1-LNL897 to female tumor-bearing nude rats (n = 3). Proteins contained in the feces pools were previously precipitated using acetonitrile and only the soluble metabolites were profiled by LC/MS with off-line RA detection. H]DM1-LNL897 were cleavage before the terminal LYS leading to metabolite M2 (LYS-MCC-DM1) and cleavage after the terminal LYS leading to M1 (MCC-DM1). Additional minor metabolites were characterized in urine and feces such as the cysteine conjugate (M7) and M6 (detected in serum and urine only) corresponding to maysine (Fig. 8) . Several additional minor components could be detected (P1, P24, and unresolved baseline RA) (see Fig. 6 ; Table 6 ), but could not be characterized with the applied analytical methods. No free DM1 or DM1 dimer could be detected in untreated excreta samples.
Excretion of RA and Mass Balance
Within 168 hours after administration, 4.15% 6 0.462% and 84.5% 6 3.12% (Table 8 ) of the administered RA was excreted in urine and feces, respectively. At the end of the experiment, i.e., at 168 hours postdose, 13.8% 6 0.482% of the administered RA was determined in the carcass. Together with the RA recovered in the cage wash (2.55% 6 0.818%) the recovery of RA was complete (105% 6 3.27%).
Discussion
This study presents the DME properties of the rat cross-reactive [ 3 H] DM1-LNL897 ADC after intravenous dosing to female tumorbearing nude rats.
Pharmacokinetics and Serum Profiles. The pharmacokinetic parameters of the radiolabeled ADC were determined by different analytical methods (ELISA, SEC, and MS) as described by Shen et al. (2012a) . By comparison of AUC last of total radiolabeled components with ELISA data (Table 1) , it is obvious that the total radiolabeled components mainly reflect the conjugated antibody, suggesting that the MCC linker of the ADC was stable in circulation as previously reported, which is different from previous observed results with trastuzumab-MCC-DM1 maytansinoid conjugate (Shen et al., 2012a) . In our opinion possible changes in the manufacturing process could contribute to these findings; however, further investigations are needed. The high stability of LNL897 in circulation is further supported by catabolite profiling and recovery measurements, which were below 1% for all time points. No DM1 could be directly detected at 1 hour postdose and about 16.3 nM of the DM1 derivate (DM1-NEM, M5; data not shown) could be detected at the same time point after derivatization, which indicates that DM1 was likely bound to endogenous substrates (glutathione and cysteine) or proteins via S-S bonds. The treatments of ADC dosing solution with increasing concentrations of TCEP have shown increased release of DM1. At the same time, the control analyses have shown that stability of the thioether bond is not affected by the presence of TCEP and that only species with disulfide bonds are affected. Based on this experiment, we concluded that minor amounts of DM1 are directly bound to cysteines. This cysteine-bound DM1 species could be released as cysteine-DM1 conjugates (such as M7) after lysosomal processing. However, glutathione conjugates of DM1 after intravenous dosing of DM1 to rats have been reported recently . Further degradation of glutathione conjugates to cysteine could also lead to formation of M7.
Compared with the ELISA data, the SEC-RA profiles provided more insights about the circulating components. As shown in Fig. 2 , SEC-RA allows the differentiation between ADC and higher molecular weight aggregates/complexes, while for the ELISA it is unclear how these additional aggregates/complexes impact the detection. When the main ADC peak and earlier eluting small peaks were summed, serum concentrations were approximately the same as those measured by the ELISA method ( Fig. 2; Tables 1 and 4) .
With SEC-RA profiles, it is only possible to distinguish between fractions of large molecules and small molecules. For the late eluting peaks, which are attributed to small molecules, it is possible that these peaks contain multiple coeluting components. Therefore, the supernatants after protein precipitation were injected and reprofiled on an analytical LC-MS system.
The metabolite profiles in serum and urine showed qualitative and quantitative differences depending on whether or not the previously described derivatization method was applied (Figs. 4 and 6; Table 5 ). A front peak as well as metabolites M7, M6, and M1 were detected with both sample preparation methods, whereas M5 was only detected after applying the derivatization method. It is worth mentioning that only limited control experiments were conducted for the distribution, metabolism, and excretion studies. Since possible S-S bond formation was identified as the main liability, the sample methods without TCEP were tested first with the DM1 dimer to make sure not to cause any reduction. A front peak was also detected during the distribution, metabolism, and excretion study in rats for the trastuzumab-MCC-DM1 maytansinoid conjugate and was attributed to tritiated water (Shen et al., 2012a) . Since our samples were dried during processing, the front peak cannot be fully attributed to tritiated water. Hence, the presence of further polar catabolites eluting in the front peak cannot be excluded.
Under the conditions of derivatization, M7 could form DM1-NEM (M5). M5 was only detected after derivatization, and the recoveries of RA from serum were also slightly higher (up to 5%), which could indicate that protein-bound DM1 was released by the derivatization method. On the other hand, it cannot be excluded that the derivatization method destroys antibodies to a minor extent, which could also lead to a slightly higher amount of RA in the solution.
Distribution. In previous studies, either tritium labels on the payload with lower specific activity (Shen at al., 2012a) or with 125 I labels on the antibody were synthesized, of which only the iodinated material was used to perform QWBA studies . In our study, the confirmed stability of the ADC in the dosing solution allowed for the QWBA experiment to be performed with a tritium label on the DM1 payload.
In rats, P-cadherin is mainly expressed in tumors and tissues such as the tongue, skin, esophagus, and bladder (internal data not shown). After intravenous dosing of the ADC, the tissue distribution as determined by QWBA was comparably low in all tissues analyzed with the exception of tumor tissue, where the highest AUC last value was determined to be 1.54-fold higher than that in blood (Table 2 ). In the remaining tissues, the exposure based on AUC last was 0.184-to 0.950-fold higher than the AUC last value of blood. This demonstrates a clear distribution of ADCrelated radiolabeled components into the tumor as the target tissue. The exposure in other tissues also indicates that non-target-specific distribution occurs, which is also nicely illustrated in Fig. 3 . Besides tumor, there was no accumulation or tissue retention of RA over time in any of the tissues analyzed (data not shown). Similar to small molecules, biotherapeutics are also cleared through kidney and liver (Hamuro and Kishnani, 2012) . Although these tissues are highlighted in the depicted QWBA pictures, it needs to be recognized that the organs are also highly perfused by blood, which contains large amounts of ADC (Fig. 3) . However, since QWBA data only show the distribution of total radiolabeled components and only the DM1 part of ADC was radiolabeled, it is unclear whether the observed RA in tissues could be attributed to intact ADC, released DM1, or another catabolite. Therefore, further investigations were conducted. Figure 5 shows the tumor profiles acquired by SEC-RA and it is obvious that after 1 hour tumor tissue mainly contained ADC, while after 24 hours the catabolite LYS-MCC-DM1 (M2) was the predominant component (Table 6) . To see if the catabolite M2 was evenly distributed in tumor tissue, the newly developed LESA-mLC-MS/MS (Lanshoeft et al., 2016) was applied. The acquired quantitative LESA data showed no significant difference over tumor tissue (Table 7 ) and the measured concentration data were well in line with the results from RA profiling in tissues (Fig. 9) , considering that analyzed tumor samples were collected from different rats with different tumor sizes.
In line with previous results, the LYS-MCC-DM1 catabolite was confirmed as the main component in the liver (data not shown) by applying the LESA-mLC-MS/MS method on QWBA slices, which is in dmd.aspetjournals.org line with early observations (Erickson and Lambert, 2012) . The main advantages of the LESA-mLC-MS/MS method are that no radiolabel is ultimately needed and no sample processing is required, thus it can provide complimentary data. For quantitative assessments without radiolabel, more thorough validation using internal standards to correct for different tissue responses would need to be applied (Lanshoeft et al., 2016) .
Elimination. Similar to serum, differences in the catabolite profiles in urine were observed with and without derivatization. In untreated urine LYS-MCC-DM1 (M2) and the cysteine-conjugated DM1 (M7) were the main components, followed by maysine (M6) and MCC-DM1 (M1). After applying the derivatization method, the peak corresponding to M7 was reduced and M5 appeared in the sample (Fig. 6 ). This could indicate that either the derivatization was not complete or that further uncharacterized components coelute under the M7 peak. These findings are in line with previous observations (Shen et al., 2012a) , except that maysine (M6) as well as the cysteine conjugate of DM1 (M7) have not been reported before. In a recent rat in vivo study with DM1, maytansinol has been reported as a catabolite , but it remains unclear if the detected maysine is a downstream product of maytansinol.
The presence of MCC-DM1 in plasma and excreta suggests that this is probably cleaved off in plasma or other tissues from the ADC. Different mechanisms for hydrolysis of the maleimide ring, which could lead to loss of DM1, have been recently described for cysteine-linked ADCs (Shen et al., 2012b) , but not for LYS-linked ADCs. It also cannot be excluded during synthesis that reactive N-Hydroxysuccinimid esters can react and couple with other amino acids such as serine and threonine (Hermanson, 2013) , which could lead to formation and release of MCC-DM1. Further investigations are required to investigate how MCC-DM1 is released.
The elimination of LNL897 was moderately fast and the results were aligned with previously reported results (Shen et al., 2012a) . After 1 week, a complete mass balance was obtained (105% 6 3%); 88.7% of the dose was detected in the collected excreta and 13.8% in the carcass (data not shown). To obtain a complete excretion profile (to reduce the amount of the dose retained in the carcass), a longer sampling time up to 2 weeks is recommended for future DME studies of ADCs.
Conclusions
We have demonstrated that the use of a tritium label on the payload of an ADC is suitable even for longer-term DME and QWBA studies. We have also shown that a diverse set of analytical methods is required to investigate all DME properties of an ADC and that the combination of QWBA and LESA-mLC-MS/MS is a powerful tool, which can give new insights into the distribution of these constructs. Label-free distribution studies may also be possible in the future if the quantitative abilities of the LESA method can be further improved. For metabolism investigations of antibody maytansoid conjugates, it is important to pay attention to the sample preparation method, especially to the use of reductive agents, since this has an impact on the observed catabolite profile. In this study, we identified a DM1-cysteine conjugate and maysine as additional catabolites. MCC-DM1 was also identified as a major component in excreta. This suggests that there must be additional mechanisms present that cause its release, which need to be further investigated. The methods presented provide useful perspectives for the further development of in vivo applications of ADCs as therapeutics.
